Will Canada’s Multi-Center Approval Processes Help Your Oncology Clinical Trial Exceed Pivotal Milestones?
For the Sponsor choosing Canada to help meet and exceed pivotal corporate objectives on their oncology trial, First Site Opened…
Exploring a ‘Rescue’ Strategy for Your Oncology Clinical Trial?
Although not formally defined within the industry, the term ‘rescue’ is commonly linked with clinical trials where enrollment is falling…
Navigating Canadian Regulations for Oncology Clinical Research – Part II
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part II Senior executives from oncology drug developers looking to…
20 Years of Unparalleled Canadian Oncology Clinical Research Experience
Scimega Research, Canada’s premier oncology contract research organization (CRO), was founded twenty years ago by two dynamic entrepreneurs, Denise Deakin…
Navigating Canadian Regulations for Oncology Clinical Research – Part I
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part I Senior executives from oncology drug developers looking to…
Proven Approach to Site Selection is Attracting More Cutting-Edge Oncology Trials to Canada
12 Early-Phase Oncology Programs Started-Up in Canada Over Last 18-Months
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
Leveraging Canada For Quicker Oncology Site Start-Up
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.
How to Start-Up 9 Oncology Sites in 9 weeks
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
The Secret to Oncology Clinical Trial Performance – An Interview with Denise Deakin
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…
Top 5 Questions asked by Directors of Clinical Operations
I sat down recently with three of our Oncology Leads and asked them what questions they hear most often from…